Remote Ischemic Preconditioning Attenuates Oxidative Stress during Cardiopulmonary Bypass
AbstractBackground: Deep hypothermic circulatory arrest (DHCA) is used to overcome the threat of cerebral ischemia during complex surgical operations of the heart and the aortic arch. Remote ischemic preconditioning (RIPC) has been shown to mitigate neurological damage.
Methods: We analyzed blood samples in a consecutive series of 52 piglets that underwent a 60-min period of DHCA with RIPC (the RIPC group) or without (the control group), to reveal whether the protective effect to oxidative stress could be seen by measuring serum 8-hydroxydeoxyguanosine (8-OHdG). The piglets were cannulated and cooled to 18°C using a heart-lung machine, for the DHCA. The piglets were then rewarmed to normothermic temperature. Blood sampling was taken at baseline, after 30 minutes of cooling,
2 hours postoperatively, and 8 hours postoperatively, and analyzed. 8-hydroxydeoxyguanosine (8-OHdG) from blood samples was analyzed by using Enzyme Linked Immunosorbent Assay (ELISA).
Results: The serum 8-OHdG concentration was lower in the RIPC group after the cooling phase, 1.84 (1.44-2.17) ng/mL, and at 8 hours after HCA 1.48 (1.39-1.69) ng/mL, when compared with the control group, where the values were
2.14 (1.81-2.56) and 1.84 (1.62-2.44) ng/mL, respectively
(P = .025) and (P = .004).
Conclusion: Remote ischemic preconditioning lowers oxidative stress during cardiopulmonary bypass.
Arvola O, Haapanen H, Herajärvi J, et al. 2016. Remote ischemic preconditioning reduces cerebral oxidative stress following hypothermic circulatory arrest in A porcine model. Semin Thorac Cardiovasc Surg [In press].
Birkelund T, Obad DS, Matejec R, Botker HE, Ravn HB. 2015. Remote ischemic preconditioning does not increase circulating or effector organ concentrations of proopiomelanocortin derivates. Scand Cardiovasc J 49:257-63.
Byrne CJ, McCafferty K, Kieswich J, et al. 2012. Ischemic conditioning protects the uremic heart in a rodent model of myocardial infarction. Circulation 125:1256-65.
Chiou CC, Chang PY, Chan EC, Wu TL, Tsao KC, Wu JT. 2003. Urinary 8-hydroxydeoxyguanosine and its analogs as DNA marker of oxidative stress: Development of an ELISA and measurement in both bladder and prostate cancers. Clin Chim Acta 334:87-94.
Franke A, Lante W, Fackeldey V, et al. 2005. Pro-inflammatory cytokines after different kinds of cardio-thoracic surgical procedures: Is what we see what we know? Eur J Cardiothorac Surg 28:569-75.
Garcia-Dorado D, Rodriguez-Sinovas A, Ruiz-Meana M, Inserte J, Agullo L, Cabestrero A. 2006. The end-effectors of preconditioning protection against myocardial cell death secondary to ischemia-reperfusion. Cardiovasc Res 70:274-85.
Granger DN, Kvietys PR. 2015. Reperfusion injury and reactive oxygen species: The evolution of a concept. Redox Biol 6:524-51.
Griepp RB. 2001. Cerebral protection during aortic arch surgery. J Thorac Cardiovasc Surg 121:425-7.
Haapanen H, Herajarvi J, Arvola O, et al. 2016. Remote ischemic preconditioning protects the spinal cord against ischemic insult: An experimental study in a porcine model. J Thorac Cardiovasc Surg 151:777-85.
Halestrap AP. 2006. Mitochondria and preconditioning: A connexin connection? Circ Res 99:10-12.
Hamilton ML, Guo Z, Fuller CD, et al. 2001. A reliable assessment of 8-oxo-2-deoxyguanosine levels in nuclear and mitochondrial DNA using the sodium iodide method to isolate DNA. Nucleic Acids Res 29:2117-26.
Hausenloy DJ, Candilio L, Evans R, et al. 2015. Remote ischemic preconditioning and outcomes of cardiac surgery. N Engl J Med 373:1408-17.
Heusch G, Botker HE, Przyklenk K, Redington A, Yellon D. 2015. Remote ischemic conditioning. J Am Coll Cardiol 65:177-95.
Jensen HA, Loukogeorgakis S, Yannopoulos F, et al. 2011. Remote ischemic preconditioning protects the brain against injury after hypothermic circulatory arrest. Circulation 123:714-21.
Li C, Xu M, Wu Y, Li YS, Huang WQ, Liu KX. 2014. Limb remote ischemic preconditioning attenuates lung injury after pulmonary resection under propofol-remifentanil anesthesia: A randomized controlled study. Anesthesiology 121:249-59.
Mazurek A, Berardini M, Fishel R. 2002. Activation of human MutS homologs by 8-oxo-guanine DNA damage. J Biol Chem 277:8260-6.
McCullough JN, Zhang N, Reich DL, et al. 1999. Cerebral metabolic suppression during hypothermic circulatory arrest in humans. Ann Thorac Surg 67:1895-9; discussion 1919-21.
Meybohm P, Bein B, Brosteanu O, et al. 2015. A multicenter trial of remote ischemic preconditioning for heart surgery. N Engl J Med 373:1397-1407.
Raedschelders K, Ansley DM, Chen DD. 2012. The cellular and molecular origin of reactive oxygen species generation during myocardial ischemia and reperfusion. Pharmacol Ther 133:230-55.
Shibutani S, Takeshita M, Grollman AP. 1991. Insertion of specific bases during DNA synthesis past the oxidation-damaged base 8-oxodG. Nature 349:431-4.
Suleiman MS, Zacharowski K, Angelini GD. 2008. Inflammatory response and cardioprotection during open-heart surgery: The importance of anaesthetics. Br J Pharmacol 153:21-33.
Walsh M, Whitlock R, Garg AX, et al. 2016. Effects of remote ischemic preconditioning in high-risk patients undergoing cardiac surgery (remote IMPACT): A randomized controlled trial. CMAJ 188:329-36.
Yannopoulos FS, Makela T, Niemela E, et al. 2010. Improved cerebral recovery from hypothermic circulatory arrest after remote ischemic preconditioning. Ann Thorac Surg 90:182-8.
Yannopoulos F, Makela T, Arvola O, et al. 2012. Remote ischemic precondition preserves cerebral oxygen tension during hypothermic circulatory arrest. Scand Cardiovasc J 46:245-50.
Yannopoulos FS, Arvola O, Haapanen H, et al. 2014. Leg ischaemia before circulatory arrest alters brain leucocyte count and respiratory chain redox state. Interact Cardiovasc Thorac Surg 18:272-7.
Yildirim F, Iskesen I, Kurdal AT, et al. 2016. Is “attenuation of oxidative stress” helpful to understand the mechanism of remote ischemic preconditioning in cardiac surgery? J Cardiothorac Vasc Anesth 30:134-40.
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).